Welcome to our dedicated page for Haoxi Health Technology news (Ticker: HAO), a resource for investors and traders seeking the latest updates and insights on Haoxi Health Technology stock.
Haoxi Health Technology Limited reports news on its China-based online marketing solutions business serving healthcare advertiser clients. The company provides campaign planning, content production, media placement, data analysis and optimization for online advertising, with activity centered on short video, news feed and social media platforms through its operating entity Beijing Haoxi Digital Technology Co., Ltd.
Recurring developments include financial results, framework contracts for digital advertising services, customized livestreaming agency services, AI-related marketing and health-management collaborations, Nasdaq listing compliance matters, reverse share-split actions and equity financing activity involving Class A ordinary shares and related securities.
Haoxi Health Technology (NASDAQ: HAO) entered a definitive agreement for a $6.5 million registered direct offering, selling 9,000,000 Class A shares and 16,999,998 pre-funded warrants at $0.25 per share. Closing is expected around May 12, 2026. Net proceeds will fund working capital and general corporate purposes.
Haoxi Health (NASDAQ: HAO) and Eaglepoint AI (subsidiary of GMM) signed a three-year strategic cooperation to develop an AI health management platform in China. The partnership will combine Haoxi's marketing networks and user reach with Eaglepoint's Aquila data engine for R&D, model training, and a SaaS release called "AI Digital Health Manager" targeting sub-healthy and chronic disease populations.
The collaboration covers intelligent nutrition, chronic disease risk assessment, and digital therapeutics, with Eaglepoint handling model iteration and data-security compliance.
Haoxi Health Technology (HAO) has announced the launch of its customized livestreaming agency strategy through its subsidiary Haoxi Beijing. The initiative focuses on providing personalized livestreaming agency services to medical aesthetics clients.
The new service offers a full-cycle, closed-loop approach from pre-campaign planning to post-campaign analysis, specifically targeting the 'light medical aesthetics' segment including laser and injection-based treatments. The comprehensive service package includes account setup, content planning, short video marketing, livestream ad strategy, and platform resource integration.
This strategic move aims to integrate evolving consumer behaviors with platform-specific operational strategies, building upon the company's established advertising delivery model and long-term client servicing experience in the healthcare sector.
Haoxi Health Technology (HAO) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received formal notification from Nasdaq confirming compliance with Listing Rule 5550(a)(2), which mandates maintaining a minimum bid price of $1.00 per share for Class A ordinary shares.
The compliance was achieved after HAO's closing bid price remained at or above $1.00 per share for ten consecutive business days, spanning from January 27, 2025, to February 7, 2025. With this achievement, the bid price deficiency matter has been resolved and closed.
Haoxi Health Technology (HAO) announced a 1-for-25 reverse share split, approved by shareholders on January 10, 2025, effective January 27, 2025. The split will reduce outstanding Class A ordinary shares from 53.29 million to 2.13 million and Class B ordinary shares from 17.27 million to 0.69 million.
The company's shares will continue trading on the Nasdaq Capital Market under the symbol 'HAO' with a new CUSIP number G4290F118. The par value will be adjusted to $0.0025 per share. Fractional shares will be rounded up to the nearest whole share. While the stock price is expected to trade at approximately 25 times the pre-split price, the company cannot guarantee sustained price levels.
Haoxi Health Technology (HAO) announced that its subsidiary Beijing Haoxi Digital Technology has secured a RMB30 million Framework Contract to provide digital advertising services for Tengyuan Media Advertising and its clients. Under the agreement, Beijing Haoxi will deliver customized internet marketing services through its media platform network over the next year. The company will utilize its marketing expertise to enhance competitiveness for Tengyuan and its clients. The partnership is described as a strategic milestone that aims to strengthen HAO's service capabilities and market position in the digital marketing industry.
Haoxi Health Technology (HAO) received a notification from Nasdaq on October 31, 2024, regarding non-compliance with the minimum bid price requirement. The company's stock failed to maintain the required $1.00 minimum bid price for 30 consecutive business days from September 19 to October 30, 2024. HAO has been granted 180 calendar days, until April 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may face delisting, though it may be eligible for additional time. HAO is considering options including a potential reverse share split to meet requirements.
Haoxi Health Technology (HAO) reported strong financial results for fiscal year 2024. Net revenue increased 72% to $48.52 million, up from $28.23 million in 2023. Gross profit rose 33% to $2.75 million, while net income grew 33% to $1.29 million. The company expanded its customer base from 393 to 543 clients, with average revenue per client increasing from $71,830 to $89,355. HAO's cash position strengthened to $6.66 million from $1.20 million year-over-year. The company recently closed a $12 million follow-on offering and announced a strategic partnership with AI platform Gauss Intelligence.
Haoxi Health Technology (HAO), an online marketing solution provider in Beijing, China, has announced preliminary unaudited financial results for FY24 ended June 30, 2024. The company projects 72% revenue growth to approximately $48.52 million, up from $28.23 million in FY23. Gross profit is expected to increase by 33.4% to $2.75 million, while net income is projected to rise 33.2% to $1.29 million.
HAO attributes this growth to its strategic development in online advertising solutions, particularly through short video formats and news feed ads. The company's proprietary data analysis software, Bidding Compass, has reportedly optimized ad placements, driving revenue and profit growth. Total assets increased to $15.51 million from $4.46 million at the end of FY23, reflecting operational scale and capital utilization post-IPO in January 2024.
Haoxi Health Technology (HAO) has announced a strategic partnership with Global Mofy AI 's subsidiary, Gauss Intelligence (Beijing) Technology Co., The collaboration aims to integrate Gausspeed, an advanced generative AI platform, with HAO's extensive application scenarios to create innovative AI marketing solutions.
The partnership will focus on three key areas: enhancing big data analysis, automating creative content generation, and improving intelligent decision-making processes. Global Mofy, a leading digital asset bank in China managing over 100,000 digital assets, will provide AI capabilities through Gausspeed. HAO will contribute its industry knowledge and practical application expertise.
Gausspeed, launched in 2024, uses Physics AI to simulate intelligent behavior, build and navigate complex 3D environments, and enable sophisticated interactions among digital assets. This collaboration is expected to revolutionize digital marketing approaches and drive digital transformation across the marketing landscape.